Press Release

HIGH POINT, N.C.--(BUSINESS WIRE)--Nov. 16, 2016-- vTv Therapeutics Inc. (vTv, Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered small molecule drug candidates to fill significant unmet medical needs, today announced that Dr. Bobby Thomas, Associate Professor at Medical College of Georgia, Georgia Regents University at Augusta, will present a poster at the Society for Neuroscience 2016 meeting in San Diego, featuring new pre-clinical data on a vTv small molecule drug candidate against Parkinson’s disease (PD).

vTv has identified novel non-electrophilic Nrf2/Bach1 modulators that can activate nuclear factor-E2 related factor (“Nrf2”) and inhibit Bach1 (the Antioxidant Response Element (“ARE”) transcriptional repressor) leading to potent activation of the Nrf2 pathway. The results from the laboratory of Dr. Thomas suggest (1) Bach1 may be a promising novel target for drug development against Parkinson's disease, and (2) vTv's compound, HPPE, may protect against nigrostriatal dopaminergic neurodegeneration by virtue of its ability to activate neuroprotective Nrf2/ARE genetic response in a preclinical mouse model of Parkinson's disease.

Based on recent findings, aberrant oxidative stress and inflammation play a key role in the pathogenesis of PD and preclinical studies suggest that activating the Nrf2/Bach1 pathway could have disease modifying effects on PD. Current pharmacological approaches targeting the Nrf2 pathway presents safety and tolerability issues as these pharmacophores contain reactive electrophilic groups.

Parkinson's disease is a progressive and debilitating neurodegenerative movement disorder characterized by marked nigrostriatal dopaminergic cell loss in the brain. No preventive therapy or cure is yet available for PD.

Dr. Thomas will be available to discuss the findings at the Society for Neuroscience 2016 meeting on Wednesday Nov. 16 from 1-5:00 pm at poster #19, Hall D-H at San Diego Convention Center.

About vTv Therapeutics

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.

The company's Alzheimer’s disease drug candidate, azeliragon, is a novel oral small molecule antagonist of the Receptor for Advance Glycation Endproducts (RAGE) with first-in-class potential.

The azeliragon development program has been granted Fast Track Designation and agreement on its Phase 3 protocol has been reached with FDA via a Special Protocol Assessment (SPA). Enrollment of part A of the Phase 3 STEADFAST study in patients with mild Alzheimer's disease was completed during the third quarter and topline data from this part of the study is anticipated to be reported in early 2018.

vTv is also pursuing the clinical development of TTP399, a novel liver selective Glucokinase Activator (GKA) with first-in-class potential for the treatment of type 2 diabetes. The company recently announced positive top line results from the six month phase 2b AGATA Study in subjects with type 2 diabetes.

vTv’s second diabetes drug candidate, TTP273, is an oral, small molecule GLP-1R agonist with best-in-class potential. The company reported the completion of enrollment of the three month Phase 2 LOGRA study in the third quarter with data readout expected at the end of 2016. The previous Phase 1b trial of TTP273 demonstrated robust effects on postprandial and fasting glucose. All doses of TTP273 were well tolerated with no serious adverse events or evidence of gastrointestinal side effects compared to placebo.

Forward-Looking Statements

This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures or investments we may undertake. We qualify all of our forward-looking statements by these cautionary statements.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161116005900/en/

Source: vTv Therapeutics Inc.

vTv Therapeutics
Investors
IR@vtvtherapeutics.com
or
Media
Nura Strong, 336-841-0300 X164
PR@vtvtherapeutics.com